RegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA Plans
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...